Ketata Hafed, Bouacida Mahdi, Bouhlel Abdelkader, Sahnoun Ahmed, Bahloul Ali, Yaich Soumaya, Hachicha Jamil, Mhiri Mohamed Nabil
Department of Urology, CHU Habib Bourguiba, Sfax, Tunisia.
Saudi J Kidney Dis Transpl. 2008 Nov;19(6):973-5.
Immunosuppressed renal transplant recipients seem to be at significantly increased risk of developing neoplasms comparatively to nonimmunosuppressed individuals. A history of malignancy exposes the patient to a high risk for relapse after transplantation. We present a trans-plant recipient with a history of an ovarian mixed germ-cell tumor, with choriocarcinoma component, which was treated seven years prior to transplantation. After three years of follow-up, there was no evidence of tumor relapse. To our knowledge, there is no report of such case in the English literature. Regarding our case report and patients with a history of ovarian germ-cell neoplasm, waiting time before transplantation must take into consideration the stage of the tumor, its prognosis, the proportion of different tumor components, and the overall prognosis of the patient if transplantation is withheld.
与未接受免疫抑制的个体相比,免疫抑制的肾移植受者发生肿瘤的风险似乎显著增加。恶性肿瘤病史使患者在移植后有很高的复发风险。我们报告一例有卵巢混合性生殖细胞肿瘤病史的移植受者,该肿瘤含绒毛膜癌成分,在移植前7年接受过治疗。经过3年的随访,没有肿瘤复发的证据。据我们所知,英文文献中尚无此类病例的报道。关于我们的病例报告以及有卵巢生殖细胞肿瘤病史的患者,移植前的等待时间必须考虑肿瘤的分期、预后、不同肿瘤成分的比例以及如果推迟移植患者的总体预后。